Bellicum Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Bellicum Pharmaceuticals은 연평균 44.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 19.1%의 비율로 수입이 증가했습니다. 매출은 연평균 0.8%의 비율로 감소했습니다.

주요 정보

44.5%

수익 성장률

64.3%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-0.8%
자기자본 수익률	-486.1%
순이익	-1,484.0%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Aug 11

Bellicum launches $25M underwritten offering

Oct 29

수익 및 비용 분석

Bellicum Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:BLCM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 23	2	-22	7
30 Jun 23	2	-29	7
31 Mar 23	2	-25	6
31 Dec 22	2	-25	6
30 Sep 22	2	-16	6
30 Jun 22	6	-8	6
31 Mar 22	6	-6	6
31 Dec 21	6	-10	7
30 Sep 21	6	7	9
30 Jun 21	1	4	11
31 Mar 21	1	-37	13
31 Dec 20	1	-8	16
30 Sep 20	5	-55	18
30 Jun 20	5	-87	23
31 Mar 20	7	-70	27
31 Dec 19	7	-112	30
30 Sep 19	2	-111	31
30 Jun 19	3	-102	29
31 Mar 19	1	-100	27
31 Dec 18	1	-98	25
30 Sep 18	1	-93	23
30 Jun 18	1	-92	21
31 Mar 18	0	-93	21
31 Dec 17	0	-92	21
30 Sep 17	0	-90	20
30 Jun 17	0	-84	20
31 Mar 17	0	-76	19
31 Dec 16	0	-69	17
30 Sep 16	0	-66	17
30 Jun 16	0	-62	16
31 Mar 16	0	-56	15
31 Dec 15	0	-49	13
30 Sep 15	0	-106	11
30 Jun 15	1	-97	8
31 Mar 15	1	-90	6
31 Dec 14	2	-85	4
30 Sep 14	3	-14	3
30 Jun 14	3	-12	3
31 Mar 14	2	-10	3
31 Dec 13	2	-9	2

양질의 수익: BLCM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: BLCM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: BLCM 은(는) 수익성이 없지만 지난 5년 동안 연간 44.5% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 BLCM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: BLCM 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: BLCM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -486.06% )을 갖습니다.

Bellicum Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

Earnings released

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Consensus EPS estimates fall by 39%

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Price target decreased to US$5.00

Insufficient new directors

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$5.00

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: US$4.65

Price target lowered to US$4.50

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum launches $25M underwritten offering

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - US$6.28

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기